NASD · Abiomed Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $1.03B | $847.52M | $840.88M | $445.30M | $593.75M | $445.30M |
| Cost of Revenue | $188.16M | $161.91M | $151.31M | $70.63M | $50.42M | - |
| Gross Profit | $843.60M | $685.62M | $689.58M | $374.68M | $543.33M | - |
| R&D | $163.40M | $121.88M | $98.76M | $93.50M | $75.30M | $66.39M |
| SG&A | $423.49M | $334.18M | $341.60M | $321.55M | $262.73M | $218.15M |
| Total Operating Expenses | $891.03M | $456.06M | $440.36M | $415.05M | $338.03M | $284.54M |
| D&A | $28.09M | $24.10M | $20.43M | $14.12M | $11.01M | $6.20M |
| Operating Income | $140.72M | $229.56M | $249.22M | $224.81M | $157.14M | $90.14M |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $54.05M | $62.70M | $53.82M | $4.34M | $48.27M | $39.23M |
| Net Income | $136.50M | $225.53M | $203.01M | $259.02M | $112.17M | $52.12M |
| EPS - Basic | $3.00 | $5.00 | $4.49 | $5.77 | $2.54 | $1.21 |
| EPS - Diluted | $2.98 | $4.94 | $4.43 | $5.61 | $2.45 | $1.17 |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $132.82M | $232.71M | $192.34M | $121.02M | $42.98M | $39.04M |
| Accounts Receivable | $90.61M | $97.18M | $84.65M | $90.81M | $70.01M | $54.05M |
| Inventory | - | $81.06M | $90.09M | $80.94M | $50.20M | $34.93M |
| Accounts Payable | $35.35M | $34.84M | $32.77M | $32.19M | $23.57M | $20.62M |
| Current Assets | $976.47M | $787.97M | $635.86M | $677.20M | $494.27M | $326.96M |
| Total Assets | $1.67B | $1.49B | $1.22B | $1.05B | $786.38M | $550.41M |
| Current Liabilities | $138.46M | $128.97M | $131.88M | $106.00M | $84.68M | $69.62M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $170.07M | $164.68M | $151.00M | $117.46M | $96.85M | $98.34M |
| Stockholders' Equity | $1.50B | $1.33B | $1.07B | $936.89M | $689.52M | $452.07M |
| Retained Earnings | $964.51M | $828.01M | $602.48M | $399.47M | $140.46M | ($46.96M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $285.39M | $274.58M | $314.92M | $252.20M | $192.55M | $115.12M |
| Investing Cash Flow | ($380.99M) | ($223.34M) | ($125.45M) | ($126.33M) | ($180.76M) | ($126.33M) |
| Financing Cash Flow | ($2.20M) | ($8.07M) | ($117.72M) | $3.87M | ($9.14M) | $3.87M |
| CapEx | $35.76M | $53.38M | $44.01M | $44.00M | $55.86M | $50.41M |
| Free Cash Flow | $249.63M | $221.19M | $270.91M | $208.19M | $136.68M | $64.70M |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 81.8% | 80.9% | 82.0% | 84.1% | 91.5% | - |
| Operating margin | 13.6% | 27.1% | 29.6% | 50.5% | 26.5% | 20.2% |
| EBITDA margin | 16.4% | 29.9% | 32.1% | 53.7% | 28.3% | 21.6% |
| Net margin | 13.2% | 26.6% | 24.1% | 58.2% | 18.9% | 11.7% |
| Free cash flow margin | 24.2% | 26.1% | 32.2% | 46.8% | 23.0% | 14.5% |
| FCF / Net income | 1.83 | 0.98 | 1.33 | 0.80 | 1.22 | 1.24 |
| R&D / Revenue | 15.8% | 14.4% | 11.7% | 21.0% | 12.7% | 14.9% |
| SG&A / Revenue | 41.0% | 39.4% | 40.6% | 72.2% | 44.3% | 49.0% |
| Effective tax rate | 28.4% | 21.8% | 21.0% | 1.6% | 30.1% | 42.9% |
| Return on assets | 8.2% | 15.1% | 16.7% | 24.6% | 14.3% | 9.5% |
| Return on equity | 9.1% | 17.0% | 19.1% | 27.6% | 16.3% | 11.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 7.05 | 6.11 | 4.82 | 6.39 | 5.84 | 4.70 |
| Quick ratio | 7.05 | 5.48 | 4.14 | 5.63 | 5.24 | 4.19 |
| Cash ratio | 0.96 | 1.80 | 1.46 | 1.14 | 0.51 | 0.56 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.11 | 1.12 | 1.14 | 1.13 | 1.14 | 1.22 |
| Liabilities / Assets | 0.10 | 0.11 | 0.12 | 0.11 | 0.12 | 0.18 |
| Efficiency | ||||||
| Asset turnover | 0.62 | 0.57 | 0.69 | 0.42 | 0.76 | 0.81 |
| Inventory turnover | - | 2.00 | 1.68 | 0.87 | 1.00 | - |
| Days sales outstanding | 32d | 42d | 37d | 74d | 43d | 44d |
| Days inventory outstanding | - | 183d | 217d | 418d | 363d | - |
| Days payable outstanding | 69d | 79d | 79d | 166d | 171d | - |
| Cash conversion cycle | - | 146d | 175d | 326d | 236d | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 21.7% | 0.8% | 88.8% | -25.0% | 33.3% | 35.1% |
| Revenue CAGR (3y) | 32.3% | 12.6% | 23.6% | 10.6% | 37.1% | - |
| Revenue CAGR (5y) | 18.3% | 20.8% | 29.6% | - | 26.5% | 23.0% |
| Gross profit growth (YoY) | 23.0% | -0.6% | 84.0% | -31.0% | - | - |
| Operating income growth (YoY) | -38.7% | -7.9% | 10.9% | 43.1% | 74.3% | 38.5% |
| Net income growth (YoY) | -39.5% | 11.1% | -21.6% | 130.9% | 115.2% | 36.6% |
| EPS growth (YoY) | -39.7% | 11.5% | -21.0% | 129.0% | 109.4% | 37.6% |
| EPS CAGR (3y) | -19.0% | 26.3% | 55.9% | 87.6% | -2.6% | - |
| EPS CAGR (5y) | 20.6% | 42.2% | 10.8% | - | 68.6% | 25.9% |
| FCF growth (YoY) | 12.9% | -18.4% | 30.1% | 52.3% | 111.3% | 5.8% |
| FCF CAGR (5y) | 31.0% | 29.3% | 48.0% | - | 174.8% | 22.4% |
| Book value growth (YoY) | 13.1% | 24.8% | 13.7% | 35.9% | 52.5% | 22.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-03-31.
Product / service
$847.52M totalImpella Product$806.32M · 95.1%
Service And Other$41.20M · 4.9%
Geographic
$847.52M totalUS$691.58M · 81.6%
Europe$105.32M · 12.4%
JP$42.87M · 5.1%
Non Us$7.75M · 0.9%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
5.44
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
7/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing ABIOMED INC against the 5 most active filers in the same SIC group.